DoJ expands crackdown on Medicare kickback schemes — Astellas and Amgen to pay nearly $125M to resolve allegations
Weeks after Jazz Pharma, Lundbeck and Alexion were disciplined by the US Department of Justice for allegedly employing charitable foundations to help cover Medicare out-of-pocket costs to urge the use of their own medicines, two other drugmakers — Astellas and Amgen — are in trouble for purportedly engaging in similar kickback schemes.
The two companies have agreed to pay the DoJ a combined $124.75 million to resolve the allegations and signed to five-year corporate integrity agreements, which require them to set up measures to promote independence from any patient assistance programs to which they donate, and to procure compliance-related certifications from company executives and board members.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.